Detail Information

Publications25

New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome

David T TeacheyDivision of Pediatric Hematology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USACurr Opin Pediatr 24:1-8. 2012

..Clinical manifestations include lymphadenopathy, splenomegaly, and autoimmune cytopenias. A number of new insights have improved the understanding of the genetics and biology of ALPS. These will be discussed in this review...

..This is the largest published series describing children with ES and documents a high rate of ALPS among pediatric ES patients. These data suggest that children with ES should be screened for ALPS with DNTs...

..The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL...

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies

David BarrettDepartment of Pediatrics, Division of Oncology, Childrens Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USAPaediatr Drugs 14:299-316. 2012

Shannon L MaudeFrom the Division of Pediatric Oncology, and Department of Pathology, Children s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PACancer J 20:119-22. 2014

..One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab. We will review the pathophysiology and management options for CRS associated with T cell-engaging therapies. ..

Yael P MosseDivision of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USAClin Cancer Res 18:6058-64. 2012

..We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237...